Open AccessNet cost of palivizumab for respiratory syncytial virus prophylaxis during the 1998/99 season in northern Alberta
Author(s) -
Sze Lap Lee,
Philip C. Etches,
Joan Robinson
Publication year - 2001
Publication title -
paediatrics and child health
Language(s) - English
Resource type - Journals
eISSN - 1918-1485
pISSN - 1205-7088
DOI - 10.1093/pch/6.8.525
Subject(s) - palivizumab , medicine , pediatrics , cost effectiveness , respiratory system , risk analysis (engineering)
Palivizumab has been shown to decrease respiratory syncytial virus (RSV) hospitalization rates in preterm infants and infants with chronic lung disease. The objective of the present study was to determine whether the use of palivizumab during the 1998/99 RSV season would have resulted in a cost-saving in infants discharged from Edmonton hospitals.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom